356TiP - Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Presenter Tony S.K. Mok
Citation Annals of Oncology (2015) 26 (suppl_9): 103-106. 10.1093/annonc/mdv528
Authors T.S.K. Mok1, F. Cappuzzo2, R.M. Jotte3, M. Reck4, V. Papadimitrakopoulou5, A. Sandler6, D. Waterkamp6, W. Verret6, Y. Shen7, M.A. Socinski8
  • 1Department Of Clinical Oncology, The Chinese University of Hong Kong, n/a - Hong Kong/CN
  • 2Istituto Toscano Tumori, Ospedale Civile, Livorno/IT
  • 3Medical Oncology, Rocky Mountain Cancer Centers, Denver/US
  • 4Department Of Thoracic Oncology, Lung Clinic Grosshansdorf, 22927 - Grosshansdorf/DE
  • 5Md Anderson Cancer Center, University of Texas, Houston/US
  • 6Clinical Science, Genentech, Inc., South San Francisco/US
  • 7Biostatistics, Genentech, Inc., South San Francisco/US
  • 8Division Of Hematology/oncology, University of Pittsburgh Medical Center, Pittsburgh/US

Abstract

Background

Treatment for advanced NSCLC includes platinum (plat)-based doublet chemotherapy (chemo), bevacizumab (bev), targeted agents for ALK+ or EGFR-mutant tumors and cancer immunotherapy targeting the PD-L1/PD-1 pathway. Atezolizumab (atezo; MPDL3280A) targets PD-L1 and inhibits binding to PD-1 and B7.1. A Ph Ib study (NCT01633970) of atezo + chemo as 1L therapy showed a manageable safety profile with promising clinical activity (ORRs 60%-75%; Liu, ASCO 2015) at all PD-L1 expression levels. Further, bev may enhance atezo antitumor responses by inhibiting VEGF-related immunosuppressive effects. Thus, 3 Ph III, multicenter, randomized open-label studies will evaluate atezo in combination with plat-based chemo (IMpower 130, 131, 150) ± bev (IMpower 150) as 1L therapy in chemo-naive patients (pts) with advanced NSCLC.

Trial design

These trials will enroll pts with previously untreated stage IV NSCLC (ECOG PS 0-1 and measurable disease per RECIST v1.1; Table). All pts must provide an archival tumor or biopsy sample at screening. Pts with untreated CNS metastases, autoimmune disease or prior immunotherapy are excluded. Stratification factors include sex, presence of liver metastases and PD-L1 expression. Per trial, pts will be randomized to receive atezo (1200 mg) with standard plat-based chemo ± bev (bev for IMpower 150 only). Induction treatment is 4 or 6 21-day cycles followed by maintenance with atezo ± bev (IMpower 150) or best supportive care. See table for primary efficacy endpoints. Secondary endpoints include ORR and duration of response per RECIST v1.1, PFS per independent review facility (RECIST v1.1), OS, safety/tolerability, pharmacokinetics and health-related quality of life. Mandatory tumor biopsies will be obtained at progression to distinguish pseudoprogression/tumor-immune infiltration from true progression and to assess biomarkers associated with response and immune escape.

Phase III Atezo Trials

Study Histology N Random- ization Experimental Arm Comparator Arm Co-Primary Endpoints (RECIST v1.1) Clinical Trials.gov Identifier
IMpower 130 Non-squamous 550 2:1 Atezo + Carboplatin + nab-Paclitaxel Carboplatin + nab-Paclitaxel 1. PFS for ITT 2. PFS for PD-L1–selected NCT02367781
IMpower 131 Squamous 1200 1:1:1 1. Atezo + Carboplatin + Paclitaxel 2. Atezo + Carboplatin + nab-Paclitaxel Carboplatin + nab-Paclitaxel 1. PFS for ITT 2. PFS for PD-L1–selected NCT02367794
IMpower 150 Non-squamous 1200 1:1:1 1. Atezo + Carboplatin + Paclitaxel 2. Atezo + Carboplatin + Paclitaxel + Bev Carboplatin + Paclitaxel + Bev 1. PFS for ITT 2. PFS for PD-L1–selected NCT02366143

Clinical trial identification

IMpower 130: GO29537; IMpower 131: GO29437; IMpower 150: GO29436

Disclosure

F. Cappuzzo: served on Advisory Boards for Roche, BMS and Pfizer. A. Sandler, D. Waterkamp, W. Verret, Y. Shen: employee of Genentech, Inc. All other authors have declared no conflicts of interest.